Tarsons Products Ltd (TARSONS)

📊 Quarterly Results (₹ Cr)

Revenue has shown consistent YoY growth, rising from ₹102 crores in September 2025 to ₹110.2 crores in June 2026, but profitability remains volatile. Operating profit turned negative in June 2026 at ₹-1 crore, down from ₹5 crore in March 2026, while net profit declined to ₹-1 crore from ₹4 crore in the prior quarter, despite EPS improvement to ₹-0.27 from ₹0.79 in March 2026. This reflects the impact of rising raw material costs (25–50% inflation) and capital deployment, even as gross margin held at 64.9% in Q1 FY27. The company is sacrificing near-term margins to scale capacity, with CAPEX of ₹160 crores underway and peak sales potential of ₹750–800 crores targeted by Q3 FY28.

🔮 Management Outlook & What's Next

Management expects margin improvement from FY28 as new facilities scale, targeting 15%+ revenue growth for FY27, with exports contributing significantly to this trajectory. The company plans to expand its international footprint by establishing localized teams across 120 countries within 5–10 years, as highlighted in the concall transcript. Despite near-term headwinds from input cost inflation and depreciation, management remains confident in the long-term profitability of its export and product diversification strategy, particularly in cell culture and labware segments.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet shows a stable equity base of ₹11 crores and reserves of ₹624 crores as of March 2026, but gross borrowings have risen to ₹393 crores, up from ₹329 crores in March 2025, indicating active capital deployment for expansion. Despite elevated gross debt, the company maintains a manageable D/E ratio of 0.52, with net debt expected to decline by ₹40–50 crores YoY, suggesting disciplined deleveraging alongside growth investments. This reflects a capital-intensive but financially controlled expansion strategy, with assets growing to ₹1,186 crores in March 2026 from ₹1,080 crores in March 2025.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Institutional interest has fluctuated significantly over the past year, with FII holdings declining from 5.82% in Q2FY26 to 0.16% in Q1FY27, while DII holdings remain minimal. Promoter holding remains stable at 47.3% across all quarters, indicating no dilution or stake sale. The sharp drop in FII participation may reflect short-term caution amid profitability headwinds, but the growing number of public shareholders (83,453 in Q1FY27) suggests retail broadening. No pledging or exit signals are evident, but the declining institutional confidence warrants monitoring.

⚖️ Peer Comparison — Healthcare

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Execution risk in commercializing new facilities in Panchla and Amta, which are central to FY28 revenue visibility. 2. Persistent raw material cost inflation (25–50%) with no sign of abatement, continuing to pressure gross margins. 3. High sensitivity to global export dynamics, including U.S. tariff risks and shipping delays, despite management’s claims of export resilience. 4. Limited product diversification beyond labware, with growth reliant on scaling existing segments rather than breakthrough innovation.

📋 Recent Filings

• 🟡 Board Meeting2026-09-28At the 43rd AGM on September 24, 2026, Tarsons Products reappointed Sanjive Sehgal as Chairman and Managing Director for a five-year term ending July …
• 🟡 voting results2026-09-28Tarsons Products Limited held its 43rd Annual General Meeting on September 24, 2026 via video conferencing. Shareholders approved all five resolutions…
• Announcement2026-09-24Tarsons Products Limited announced that its trading window will close on October 1, 2026, for all designated insiders and their immediate relatives un…
• 🟡 Board Meeting2026-09-24Tarsons Products held its 43rd AGM on September 24, 2026 via video conference, with 64 shareholders representing 70.84% of voting rights present. Chai…
• 🔴 Announcement2026-09-24Tarsons Products Limited announced it will host a virtual analyst and institutional investor meeting on Wednesday, September 30, 2026, from 5:00 PM to…
• Announcement2026-09-22Tarsons Products clarified that recent share volume increases are market-driven and no material undisclosed information exists, reaffirming compliance…
• 🔴 annual report2026-09-02Tarsons Products Ltd reported FY2025-26 revenue of ₹3,329.31 million, up from ₹3,141.77 million, with PAT margin declining to 6.81% (from 13.60%) due …
• 🟡 Board Meeting2026-09-02Tarsons Products Limited announced its 43rd AGM on September 24, 2026, via video conference, to approve audited standalone and consolidated financial …
• 🟡 Board Meeting2026-09-02Tarsons Products Limited announced its 43rd AGM on September 24, 2026, via video conference, to adopt FY2025-26 audited standalone and consolidated fi…
• 🟡 sustainability report2026-09-02Tarsons Products Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 on September 2, 2026, to BSE and NSE. T…

🧠 Analyst's Read

Tarsons is executing a capital-intensive turnaround with clear long-term ambitions in exports and product diversification, but near-term profitability remains elusive due to investment and input cost pressures. The company’s success hinges on disciplined CAPEX execution and margin recovery from FY28 onward. Investors should watch for early revenue signals from new facilities and any shift in export growth trajectory, as these will be key indicators of whether the current investment phase transitions into sustainable profitability.

Based on filing content and financial data. Not a recommendation.